Details for New Drug Application (NDA): 203697

✉ Email this page to a colleague

NDA 203697 describes VAZALORE, which is a drug marketed by Plx Pharma and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the VAZALORE profile page.

The generic ingredient in VAZALORE is aspirin. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aspirin profile page.

Summary for 203697

Tradename:	VAZALORE
Applicant:	Plx Pharma
Ingredient:	aspirin
Patents:	4

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 203697

Generic Entry Date for 203697^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: 10,786,444 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 203697

Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Decreased Platelet Aggregation Decreased Prostaglandin Production

Medical Subject Heading (MeSH) Categories for 203697

Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Cyclooxygenase Inhibitors
Fibrinolytic Agents
Platelet Aggregation Inhibitors

Suppliers and Packaging for NDA: 203697

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VAZALORE	aspirin	CAPSULE;ORAL	203697	NDA	PLx Pharma Inc	73089-081	73089-081-12	1 BLISTER PACK in 1 CARTON (73089-081-12) / 81 mg in 1 BLISTER PACK
VAZALORE	aspirin	CAPSULE;ORAL	203697	NDA	PLx Pharma Inc	73089-081	73089-081-14	81 mg in 1 CARTON (73089-081-14)

Profile for product number 001

Active Rx/OTC/Discontinued:	OTC	Dosage:	CAPSULE;ORAL			Strength	325MG
Approval Date:	Jan 14, 2013	TE:		RLD:	Yes
Patent:	10,646,431	Patent Expiration:	Sep 29, 2032	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	10,786,444	Patent Expiration:	Sep 29, 2032	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
Patent:	9,216,150	Patent Expiration:	Sep 29, 2032	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 203697

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013	8,865,187	⤷ Subscribe
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013	9,351,984	⤷ Subscribe
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013	9,101,637	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.